Tislelizumab (Tevimbra)

Tislelizumab at a glance

Tislelizumab is an immune checkpoint inhibitor given as a drip into a vein. It may be prescribed on its own or with chemotherapy. The brand name is Tevimbra. The cancer, treatment setting and product instructions determine the schedule.

Use this guide alongside the plan from your treating hospital. Keep the drug name, last treatment date and your hospital’s urgent contact details available.

How tislelizumab works

Tislelizumab blocks PD-1, a signal that normally helps keep immune responses under control. Blocking it can help immune cells attack cancer cells. It works differently from conventional chemotherapy.

The same immune activation can inflame healthy organs. A symptom can therefore need attention even if it seems unrelated to the cancer. Having side effects, or having none, does not reliably show whether treatment is working.

How your team decides whether it is suitable

Tislelizumab is used in specific treatment settings for cancers including the oesophagus, stomach or gastro-oesophageal junction, and lung; available indications differ between countries. The subtype, stage, previous treatment and relevant tumour results determine whether it is an option. It is not suitable simply because another person with the same organ affected receives it.

Some treatment combinations require a defined PD-L1 result. A tumour area positivity (TAP) score, combined positive score (CPS) and tumour-cell percentage are different scoring methods. Ask which result your prescribed regimen requires; the numbers should not be used interchangeably.

When considering checkpoint immunotherapy, your doctor may check markers such as PD-L1 (programmed death-ligand 1), MMR (DNA mismatch repair), MSI (microsatellite instability) or TMB (tumour mutational burden). These tests look at different features of the cancer: an immune-related protein, how well DNA errors are repaired, changes in short repeated DNA sequences, or the number of genetic changes in the tumour.

Not everyone needs all these tests, and they are not interchangeable. Their relevance depends on the cancer type, stage and exact medicine or combination being considered. Some treatment plans require a particular test result; others do not. Discuss with your doctor which tests are relevant to you and how the results affect your options. A result alone does not guarantee that treatment will work.

These markers do not create an approved use for every checkpoint medicine. The exact drug, cancer and treatment setting still have to match the evidence and your treatment plan.

Before treatment starts

Your team will ask about autoimmune conditions, previous organ or donor stem-cell transplantation, lung or heart disease, infections and earlier cancer treatment. Mention previous severe reactions to any immunotherapy, even if you are now well. Tell them about pregnancy, breastfeeding, any possibility of pregnancy and whether you want to discuss fertility preservation before starting.

Bring a complete medicines list, including inhalers, eye drops, steroid creams, tablets, injections, vitamins and traditional or herbal remedies. A medicine taken only occasionally can still matter. Do not stop prescribed steroids or immune-suppressing treatment yourself; the team must weigh why you need them and how they fit with treatment.

Baseline tests usually include blood counts, kidney and liver function, blood sugar and thyroid function. Other hormone tests, heart tests or infection screening depend on your history and treatment plan. Record your usual bowel pattern, breathing, energy level and any existing rash. This makes it easier to identify a change rather than attributing everything to cancer.

Before leaving the first appointment, know how to reach your own hospital’s urgent oncology service, including outside clinic hours. Keep the treatment alert card or an up-to-date medicine record with you. A family member can help remember instructions and recognise changes you may not notice yourself.

How treatment is given

Tislelizumab is given by intravenous infusion. The European product information reviewed includes 200 mg every three weeks and 400 mg every six weeks, depending on the treatment plan. Other product labels may offer different schedules. Your prescription and the product supplied determine what you receive.

For a 200 mg dose, the first infusion usually takes 60 minutes, with later infusions shortened to 30 minutes if tolerated. The 400 mg schedule has different initial infusion times: normally 120 minutes for the first dose, or 90 minutes when switching from three-weekly 200 mg treatment; the next may be 60 minutes, then 30 minutes if tolerated. A higher dose should not automatically be run over the shorter infusion time.

When chemotherapy is due the same day, tislelizumab is usually given first. Allow additional time for blood tests, review and the other medicines. Tell the nurse immediately about chills, rash, flushing, wheezing or dizziness during treatment. A missed appointment should be rearranged with the team, not made up by changing the next interval.

Monitoring and checking whether treatment is working

Before treatment, staff review symptoms and blood results to check that another dose is appropriate. Some immune problems first appear on a blood test, before you feel unwell. Thyroid, liver, kidney or glucose abnormalities may need repeat tests, additional investigations or another specialist’s advice.

Scans and, where appropriate, other disease measurements assess whether treatment is helping. Feeling well or having side effects cannot reliably tell you whether it is working. Occasionally immune inflammation complicates the interpretation of a scan; your oncologist decides whether a repeat scan or other assessment is appropriate. Worsening symptoms should still be reported promptly.

A dose may be delayed while a new symptom is investigated. Checkpoint antibodies are commonly withheld or stopped for significant toxicity rather than simply reduced to a smaller dose. This is a safety decision, not evidence that you have done anything wrong. The team balances cancer control with recovery and the risk of the same reaction happening again.

Common side effects and how to manage them

Possible effects include tiredness, rash or itching, joint discomfort, nausea, diarrhoea, reduced appetite and thyroid changes. Blood counts and liver or kidney tests can also change. The pattern is different when chemotherapy is added, and not everyone experiences the same effects.

Energy and appetite

Balance rest with gentle activity, eat small regular meals and ask for support if weight is falling. New severe weakness, dizziness or unusual thirst needs assessment for a treatable cause, including a hormone or blood-sugar problem.

Skin and joint symptoms

Use plain moisturiser and protect skin from strong sunlight. Report a new rash, persistent itching or joint pain. Ask which pain relief is safe with your other medicines. Blistering, peeling or a painful widespread rash needs urgent help.

Bowel changes

Keep track of new loose stools and contact the team promptly. Diarrhoea can mean bowel inflammation, even when initially mild. Drink fluids if you can, but do not rely on repeated over-the-counter treatment before the cause is assessed.

Blood-count changes and infection

Low blood counts can contribute to tiredness, infection or bleeding, especially with combination treatment. Report fever, chills, unusual bruising or bleeding. A new cough or breathlessness could be infection or immune lung inflammation and needs assessment.

Less common but important side effects

Checkpoint treatment can make the immune system inflame healthy organs. Several organs can be affected together. Problems may appear during treatment or after it stops, and a symptom does not have to be dramatic to deserve attention.

Lung inflammation

New cough, breathlessness or chest discomfort can reflect inflammation called pneumonitis, infection or another problem. Contact the team promptly. Severe breathlessness, blue lips, collapse or difficulty speaking because of breathing requires emergency care.

Bowel and liver inflammation

Immune colitis can cause diarrhoea, cramps, blood or mucus, and occasionally serious bowel damage. Liver inflammation may initially show only on blood tests. Yellow eyes or skin, dark urine, right-sided upper abdominal pain or unusual bruising needs prompt assessment. Do not assume an existing digestive or liver condition explains a new change.

Hormone gland problems and diabetes

Thyroid, pituitary or adrenal inflammation can cause unusual tiredness, headache, feeling cold, weight changes, dizziness or altered mood. New excessive thirst and frequent urination can signal diabetes. Vomiting with marked thirst, deep or rapid breathing, confusion or severe weakness is an emergency. Some hormone deficiencies require long-term replacement even after the immune inflammation settles.

Kidney, heart, muscle and nerve problems

Reduced urine, blood in the urine or swelling may indicate kidney injury. Also report painful or unusually frequent urination; bladder inflammation has been reported, and infection or another cause needs assessment. Chest pain, palpitations, faintness, rapid weakness, swallowing difficulty, confusion or a seizure can signal serious heart or nervous-system effects. Heart, muscle and nerve inflammation can overlap. Do not wait for all the symptoms in a list to appear.

Eye problems, severe skin reactions and transplant complications

Eye pain, light sensitivity or new blurred vision needs urgent advice. Severe rash with blistering, peeling or mouth involvement needs immediate assessment. Checkpoint activation can also cause transplant rejection or complications around a donor stem-cell transplant. Tell every treating specialist that you have received this medicine.

How immune side effects are treated

Treatment may involve temporarily withholding immunotherapy, corticosteroids, hormone replacement or other specialist medicines. Severe reactions sometimes require hospital care and permanent discontinuation. Take the steroid taper exactly as prescribed; stopping abruptly can be dangerous. Early reporting often makes management more straightforward, but no one can promise that every effect will completely reverse.

Other medicines, supplements and vaccinations

Check new prescriptions, non-prescription medicines, supplements and herbal products with the cancer team or pharmacist. Avoid products marketed as “immune boosters”: they are not proven substitutes for treatment and can complicate safety assessment. Do not assume a natural product is harmless.

Steroids may be essential to treat immune side effects, despite the medicine’s aim of activating immunity. Never withhold necessary steroids because you are worried they will cancel the treatment. Equally, do not start leftover steroid tablets yourself. If you require hormone replacement or long-term steroids, carry the relevant alert information.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines are often appropriate, but timing and response depend on the full treatment, particularly chemotherapy or immune-suppressing medicines. Live vaccines need specific specialist approval. There is no single post-treatment vaccine waiting period that is correct for every checkpoint-treated patient.

Everyday life during treatment

Eating does not alter the dose of a medicine given by infusion. Aim for adequate fluids and regular food, adjusting for nausea or diarrhoea, and follow any kidney, heart or diabetes advice already in place. Avoid restrictive diets or supplements promising to improve immune treatment response.

Work and exercise can continue if you feel able, with flexibility around appointments and fatigue. Start activity gently and reduce it when unwell. Do not drive if you are dizzy, sleepy, weak, visually affected or unable to concentrate. Premedicines and pain medicines can also impair driving. Sudden neurological symptoms require assessment, not simply a rest before driving again.

Discuss travel before booking, especially long journeys or places far from emergency care. Keep your treatment record, medicines list and enough prescribed medicines with you. Tell dentists and other clinicians about immunotherapy before procedures. Wash hands, avoid close contact with people who are clearly infectious and use food safety precautions; complete isolation is not usually necessary solely because you are receiving a checkpoint inhibitor.

Sex is generally possible if comfortable, with the contraception precautions below. Symptoms, dryness or fatigue may affect intimacy and can be discussed without embarrassment. Emotional support can help with uncertainty between scans; report persistent anxiety, poor sleep or low mood rather than carrying it alone.

Fertility, contraception, pregnancy and breastfeeding

Tislelizumab may harm a developing baby. If you could become pregnant, use effective contraception during treatment and for at least 4 months after the last dose. Tell the team promptly about pregnancy, suspected pregnancy or contraceptive failure.

Do not breastfeed during treatment or for at least 4 months after the final dose. Other medicines in your regimen may require longer precautions. The effect on future fertility is uncertain; discuss fertility preservation before treatment, particularly if chemotherapy is also planned.

After treatment finishes

Keep attending the follow-up appointments and tests recommended by your team. Immune side effects can start after the final dose, so continue to mention previous immunotherapy when seeking medical care. Keep your alert card or treatment summary accessible and tell emergency staff about the medicine even months later.

Continue prescribed hormone replacement, steroid tapering and other supportive treatment. Do not stop these because the anticancer infusion has finished. Follow the specified contraception and breastfeeding restrictions from the date of the final relevant dose. Recovery is individual; ask for rehabilitation, nutritional support or help returning to work if symptoms persist.

Frequently asked questions